High‐level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB
The DOI matches its Crossref record.
Abstract
Many human epithelial cancers, particularly those with a poor prognosis, express high levels of fatty acid synthase (FAS), a key metabolic enzyme linked to the synthesis of membrane phospholipids in cancer cells. In view of the recent finding that in the human prostate cancer cell line LNCaP, overexpression of FAS can be largely attributed to constitutive activation of the phosphatidylinositol‐3 (PI3) kinase/Akt kinase pathway, the activation status of the Akt pathway, and whether this activation coincides with increased FAS expression, was examined in clinical prostate cancer tissues. Using well‐preserved frozen prostatic needle biopsies and a sensitive Envision detection technique, S473‐phosphorylated Akt (pAkt) was found in 11/23 low‐grade prostatic intraepithelial neoplasia (PIN) lesions, in all (36/36) high‐grade PINs, and in all (86/86) invasive carcinomas. Non‐neoplastic tissues were negative. Interestingly, in low‐grade PINs and low‐grade carcinomas, pAkt was mainly cytoplasmic or membrane‐bound and was associated with moderate elevation of FAS expression. In 24/36 high‐grade PINs and 82/88 invasive carcinomas, pAkt was found at least partly in the nucleus. Greater nuclear pAkt staining, and higher FAS expression, correlated with a higher Gleason score. In the light of previous findings that pAkt plays a causative role in the overexpression of FAS in cancer cells in culture, these data strongly suggest that high‐level expression of FAS in prostate cancer tissues is linked to phosphorylation and nuclear accumulation of Akt. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fatty Acid Synthase and Cancer: New Application of an Old Pathway
Kuhajda, F. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4673 · Cited by 647
Increased lipogenesis in cancer cells: new players, novel targets
Swinnen, J. V., Brusselmans, K., & Verhoeven, G. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232894.28674.30 · Cited by 610
Self-citationFatty Acid Synthase As a Potential Therapeutic Target in Cancer
Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. (2010) · Future Oncology · doi:10.2217/fon.10.11 · Cited by 545
Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer
Migita, T., Ruiz, S., Fornari, A., Fiorentino, M., Priolo, C., Zadra, G., Inazuka, F., Grisanzio, C., Palescandolo, E., Shin, E., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp030 · Cited by 387
The Akt–SREBP nexus: cell signaling meets lipid metabolism
Krycer, J. R., Sharpe, L. J., Luu, W., & Brown, A. J. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.001 · Cited by 360
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Schlaepfer, I. R., Rider, L., Rodrigues, L. U., Gijón, M. A., Pac, C. T., Romero, L., Cimic, A., Sirintrapun, S. J., Glodé, L. M., Eckel, R. H., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0183 · Cited by 304
Ventura, R., Mordec, K., Waszczuk, J., Wang, Z., Lai, J., Fridlib, M., Buckley, D., Kemble, G., & Heuer, T. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.020 · Cited by 301
“FASN gene expression is activated downstream of the PI3K–AKT–mTOR signal transduction pathway in response to cell metabolism and growth signals, and is driven by SREBP-1, ZBTB7A, and p53 family transcription factors (Van de Sande et al., 2005; Choi et al., 2008).”
BackgroundThe fat side of prostate cancer
Zadra, G., Photopoulos, C., & Loda, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.03.010 · Cited by 291
mTOR links oncogenic signaling to tumor cell metabolism
Yecies, J. L., & Manning, B. D. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0726-6 · Cited by 183
Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
TOREN, P., & ZOUBEIDI, A. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2601 · Cited by 163
“It is unclear whether increased nuclear staining improves prognostication, as suggested by one study which found that greater nuclear phospho-Akt staining was associated with higher Gleason grade (63).”
Lin, H.-P., Cheng, Z.-L., He, R.-Y., Song, L., Tian, M.-X., Zhou, L.-S., Groh, B. S., Liu, W.-R., Ji, M.-B., Ding, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1597 · Cited by 150
“Accordingly, FASN is frequently up-regulated in many types of tumors, such as breast, prostate, liver, colon, and ovarian cancers (1-6).”
Metadata
- Authors
- Van de Sande, T., Roskams, T., Lerut, E., Joniau, S., Van Poppel, H., Verhoeven, G., & Swinnen, J. V.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2005-05-04
- Volume
- 206
- Issue
- 2
- Pages
- 214-219
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1997143054
- Cited by
- 136
- References
- 0
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.